

New Spectrophotometric Method Development and Validation of Lumefantrine

Baokar Shrikrishna^{1*}, Annadate Amol¹, Undare Santosh²

¹Department of Pharmaceutical Chemistry, SVPM's College of Pharmacy, Malegaon (Bk II), Tal-Baramati, Pune, Maharashtra, India

²P.G. Department of chemistry, Balbhim arts, science and commerce college, Beed

*krishnabaokar@gmail.com



ABSTRACT

A Simple, sensitive, specific, spectrophotometric method has been developed for the detection of Lumefantrine in pure and Pharmaceutical formulations. The optimum condition for the analysis of the drug was established. Lumefantrine shows maximum absorption at 228 nm and obeyed Beer's law in the concentration range 10 to 50 µg/ml.

The correlation coefficient was found to be 0.999 and slope of line was found to be 0.0635. The percent S.D. for intra assay precision of the method was found to be 1.85% whereas Inter assay precision was found to be 0.44%. The sample solution was stable up to 24 hours. The assay results were found to be in good agreement with label claim.

The proposed method was simple sensitive, precise, quick and useful for routine quality control.

Keywords: Spectrophotometer, Lumefantrine, Validation, Antimalarial

INTRODUCTION

Lumefantrine is an anti malarial drug widely used in malaria endemic areas^[1]. Many studies have demonstrated that it is highly effective in the treatment of resistant *P. falciparum malaria*, resulting in high cure rates and prevention against reinfection. Lumefantrine also named benflumetol and chemically (9z)-2,7-dichloro-9-((4-chlorophenyl) methyl)-a-((dibutylamino) methyl)-9H-fluorene-4-methanol with a molecular formula C₃₀H₃₂C₁₃NO is an aryl alcohol (shown in fig. No. 1)




FIG NO. 1 Lumefantrine

Anti malarial first synthesized in the 1970's by the Academy of Military Medical Sciences, Beijing, China and registered in China for the treatment of malaria in 1987^[2]. The compound is a yellow powder that is poorly soluble in water, oils, and most organic solvents, but soluble in unsaturated fatty acids and acidified organic solvents. Lumefantrine is extensively bound (~99%) to plasma proteins, mainly high density lipoproteins^[3]. The molecular structure has been presented in fig 1. Lumefantrine as a drug is commercially available only in a fixed-dose combination with artemether^[4]. Lumefantrine is having following side effects such as cough, diarrhea, dizziness, fatigue, headache, loss of appetite, nausea, vomiting and weakness. The exact mechanism of Lumefantrine is not well defined. Literature review reveals that the various analytical methods like HPLC-UV method (210 nm) for the

How to cite this article: SK Baokar, A Annadate, S Undare; New Spectrophotometric Method Development and Validation of Lumefantrine; PharmaTutor; 2014; 2(5); 148-154

simultaneous quantitation of artemether and lumefantrine in fixed dose combination tablets^[5]. Liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper^[6] solid-phase extraction and liquid chromatographic method^[7] in rat plasma by liquid-liquid extraction using LC-MS/MS with electro spray ionization^[8,9,10]. The aim of the present work is to find out a simple, specific, sensitive, spectrophotometer method developed for the detection of Lumefantrine in pure form and in pharmaceutical formulation.

EXPERIMENTATION

Instrumentation

A double beam spectrophotometer Shimadzu UV-VIS 1700 Pharmaspec LP was used for the detection of absorbance, Afcoset FX-300 as Weighing balance and Ultra pure sonicator, borosil glass apparatus were used for experimental purpose.

Chemicals and Reagents

Lumefantrine working standard was supplied by Sequent Research Limited, Mangalore, (Karnataka-India) as a gift sample. Marketed sample for the analysis which brought from local pharmacies. Lumefantrine (100mg/tablet) was manufactured by the Shreya

Pharmaceutical Pvt. Ltd. India. All other chemicals used in the analysis were AR grade.

Standard Solution

Accurately 100 mg Lumefantrine was weighed and it was diluted with 100 ml methanol. From the resulting solution 1ml was taken and made up to 100 ml to give 10ppm concentration of Lumefantrine and its absorbance was recorded.

Sample Solution

20 tablets were weighed and powdered. From this, powder equivalent to 0.379gm of Lumefantrine was taken and it was extracted with methanol and then the resulting solution is made up to 200 ml with Methanol. From the resulting solution 10 ml was taken and made up to 100 ml. then pipette out 10 ml from above solution dilute up to 100 ml with methanol, then absorbance of resulting solution was recorded

METHOD VALIDATION

Validation of the analytical method for the determination of Lumefantrine in Pure form and in pharmaceutical formulation was carried out as per ICH guidelines. All the validation parameters for Lumefantrine shown in Table No. 1

TABLE NO. 1 VALIDATION PARAMETERS FOR LUMEFANTRINE

Parameters	Lumefantrine
Measured Wavelength	228 nm
Linearity Range	10-50 ppm
Slope	0.0535
Intercept	-0.0032
Method Precision % RSD	0.1175
Correlation Coefficient	0.999

LINEARITY

The method was validated according to ICH Q2B guidelines for validation of analytical procedures in order to determine the linearity, sensitivity, precision and of the analyte^{11, 12, 13, 14} For Lumefantrine, five point calibration curves were generated with the appropriate volumes of the working standard solutions for UV methods. All the linearity data tabulated in Table No. 2 and linearity curve shown in Fig. No. 2

TABLE NO. 2 LINEARITY

Sr. No.	Concentration (ppm)	Absorbance
1	10	0.525
2	20	1.052
3	30	1.611
4	40	2.19
5	50	2.631
	Mean	1.6018
	SD	0.846625
	RSD	0.5291
	%RSD	52.91
	Correlation coeff.	0.99915
	Slope	0.0535
	Intercept	-0.0032




FIG. NO. 2 LINEARITY CURVE

ACCURACY

The accuracy of an analytical method is the closeness of the test results obtained by that method to the true value¹⁵. The accuracy of an analytical method is defined as the degree to which the determined value of analyte in a sample corresponds to the true value, which is tabulated in Table No. 3

TABLE NO. 3 ACCURACY

Sr. No.	Concentration	Absorbance	Result
1	80 %	0.990	Mean = 0.972 S. D. = 0.020 % R.S.D. = 2.088
		0.950	
		0.976	
2	100 %	1.181	Mean = 1.172 S. D. = 0.013 % R.S.D. = 0.136
		1.157	
		1.179	
3	120 %	1.352	Mean = 1.358 S. D. = 0.017 % R.S.D. = 1.280
		1.378	
		1.345	

PRECISION

The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions¹⁶.

System Precision

The precision were determined with standard quality control samples (in addition to calibration standards) prepared in triplicate at different concentration levels Performing replicate analyses of the standard solutions was used to assess the precision and reproducibility of the proposed methods. The selected concentration within the calibration

range was prepared in methanol and analyzed with the relevant calibration curves to determine the intra and inter day variability. The System and Method Precision were determined as the RSD %.

Method Precision

Method precision or intra-assay precision data are obtained by repeatedly analyzing, in one laboratory on one day, aliquots of homogeneous sample, each of which independently prepared according to method procedure.

All the data for System and Method Precision tabulated in Table No. 4 and 5 respectively.

TABLE NO. 4 SYSTEM PRECISION

Sr. No	Conc. (ppm)	Abs-1	Abs-II	Abs-III	Avg
1	20	1.052	1.071	1.052	
2	20	1.055	1.052	1.055	
3	20	1.112	1.055	1.06	
4	20	1.053	1.053	1.053	
5	20	1.052	1.053	1.052	
6	20	1.052	1.052	1.055	
	Mean	1.062667	1.056	1.0545	1.057722
	SD	0.024196	0.00743	0.002754	0.01146
	RSD	0.02276	0.007035	0.002611	0.010802
	%RSD	2.276	0.7035	0.2611	1.0802

TABLE NO.5 METHOD PRECISION

Sr. No.	Conc (ppm)	Absorbance
1	30	1.686
2	30	1.699
3	30	1.702
4	30	1.704
5	30	1.694
6	30	1.690
	Avg	1.695833
	S.D.	0.007055
	R.S.D	0.00117583
	% R.S.D	0.117583

RUGGEDNESS

The ruggedness of an analytical method is degree of reproducibility of test results obtained by the analysis of the same samples under a variety of normal test conditions, such as different laboratories, different analysts, different instruments, different lots of reagents, different elapsed assay times, different assay temperatures, different days etc. Data for ruggedness tabulated in Table No. 6

TABLE NO. 6 RUGGEDNESS

Sr. No	Parameter	Set I	Set II
1	System	Shimadzu-1700	Systronics -119
2	Sample	Batch No-X	Batch No -Y
3	Day	Monday	Tuesday
4	Date	30/01/2011	31/01/2011
5	Time	3.45pm	3.45 pm
6	Lab	Analysis	Chemistry
7	Analyst	01/07	12/07
8	Sample	20ppm	20ppm
9	Absorbance	1.016	1.013
10	Assay	99.70%	99.40%

ROBUSTNESS

The evaluation of robustness should be considered during the development and development is on the type of procedure under study. Robustness of the method was checked by making slight deliberate changes in selected conditions like change in wavelength. It was observed that there were no marked changes in chromatograms, which demonstrated that the developed method is robust¹⁷. Instruments are susceptible to variations in analytical conditions, should be suitability controlled or a precautionary statement should be including in the procedure. Robustness data tabulated in Table No. 7

TABLE NO. 7 ROBUSTNESS

Sr. No.	Concentration	Wavelength	Absorbance	Result
1	20 ppm	239	0.925	Mean = 0.925 S. D. = 0.001 % R.S.D. = 0.016
			0.927	
			0.927	
2	20 ppm	229	0.629	Mean = 0.628 S. D. = 0.002 % R.S.D. = 2.503
			0.300	
			0.625	

RESULTS AND DISCUSSION

Linearity of the drug was obtained in the range of 10ppm to 50ppm Lumefantrine. The linearity coefficient and percentage curve fitting was found to be 0.999 and 99.98% for Lumefantrine. Accuracy of the method was determined through the recovery studies of the drugs. Recovery of the drugs was well within the

acceptance limit (99% - 101%). Precision of the method was determined by intraday and interday method. Percent RSD of the analyte was found to be within the limit of 2%, thus the developed method was found to provide high degree of precision and reproducibility. Ruggedness was determined by performing the assay with same condition on

different days, by different analysts, different instrument and different column. The test results were found within limit 99 – 101%. The results were found to be reproducible, in spite of variations in conditions which could be normally expected from analysts to analysts. Robustness was determined by carrying out the assay during change in Wavelength, Percent RSD was found to be within the limit NMT 2%. The values of RSD obtained with the change in mobile phase ratio makes it possible to carry out the method for Lumefantrine with a small variation in mobile phase ratio.

CONCLUSION

UV method is developed for the Lumefantrine by using UV Spectrophotometer SCHIMADZU 1700 model. The developed method is applied

for the Lumefantrine from tablet form. The assay is within the limit. The developed method is validated with various parameters as per ICH guidelines like accuracy, precision, linearity, ruggedness and robustness. All the results obtained are within the acceptance criteria. Hence the developed method is found to be satisfactory and would be used for the routine analysis in the laboratory for Lumefantrine in pharmaceutical formulation.

ACKNOWLEDGMENT

Authors were thankful to Sequent Research Limited, Mangalore, (Karnataka-India) for providing gift sample of Lumefantrine. We would also like to thank Principal and Management of Shivnagar Vidya Prasarak Mandal's College of Pharmacy for providing all the facilities to complete this work successfully.

↓ REFERENCES

1. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP, In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). *J Infect Dis.* 2005, 191(6):1014-7.
2. World Health Organization, Practical Chemotherapy of Malaria, W.H.O.
3. Colussi D, Parisot C, Legay F, Lefevre G, Binding of artemether and lumefantrine to plasma proteins and erythrocytes *Eur J Pharm Sci.* 1999;9:9–16.
4. Blessborn D, Rösing S, Annerberg A, Sundquist D, Björkman A, Lindegårdh N, Bergqvist Y, Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper, *J Pharm Biomed Anal.* 2007, 45(2), 282-7.
5. Cesar Ida C, Andrade Nogueira FH, Antonio Pianetti G, Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection, *J Pharm Biomed Anal.* 2008 Nov. 4; 48(3): 951-4.
6. Da Costa Cesar I, Nogueira FH, Pianetti GA, Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical products, *J Pharm Biomed Anal.* 2008, 48 (1): 223-6.
7. Annerberg A, Blessborn D, Bergqvist Y, Day N, White NJ, Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma, *In J Pharm Biomed Anal.* 2005, 37 (5) : 1081-8.
8. Lindegårdh N, Wahajuddin, Singh SP, Jain GK, Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study, *J. Chromatography B.* 2009, 877(11-12): 1133-9.
9. Hodel EM, Zanolari B, Mercier T, Biollaz J, Keiser J, Ol-liaro P, Genton B, Decosterd LA, A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and

their metabolites in human plasma, *J Chromatogr B*, 2009, 877(10) : 867-86.

10. Isabela da Costa César,, Fernando Henrique Andrade Nogueira and Gérson Antônio Pianetti, Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV de-tection, *Journal of Pharmaceutical and Biomedical Analysis*, 2008; 48(3); 951-954

11. F.W. Fifield and D. Kealey, 5th Edition, Black Well Science Ltd. Principles and Practice of Analytical Chemistry, 2000, pp. 270 – 276.

12. G.C. Hokanson, A Life Cycle Approach to the Validation of Analytical Methods During Pharmaceutical Product Development, Part – II: Changes and the Need for Additional Validation, *Pharm. Tech.*, 92 -100, 1994.

13. J.M. Green. A Practical Guide to Analytical Method Validation, *Anal. Chem. News and Features*, 305A – 309A, 1996

14. J. Vessman, Selectivity or Specificity? Validation of Analytical Methods from the Perspective of an Analytical Chemist in the Pharmaceutical Industry, *J. Pharm and Biomed. Anal.*, 1996, 14, 867 – 869.

15. Shrikrishna B. Baokar, B. Shirke, V. Sivanand, G.K. Pratheesh, Analytical method development and validation for estimation of sildenafil citrate from tablet dosage form by RP-HPLC, *Int. J. Res. Phar.Sci.* 2(2), 2011, 130-136.

16. Baokar Shrikrishna, Pawar Vinod , Sonawane S.H., High Performance Liquid Chromatographic Method Development and Validation of Cholesterol Inhibitor Drug. *Journal of Pharmacy Research*, 2011,4(7),2313-2316

17. Baokar Shrikrishna B., Erande R.S., Shaikh S.G. Analytical Method Development and Validation for Estimation of Ezetimibe from Tablet Dosage Form by Using RP-HPLC, *Int. J. of Res. in Pharm. and Biomed. Sci.*, Vol. 2 (2), Apr – Jun 2011, 833-841